Hyperthermia and Thermosensitive Liposomes for Improved Delivery of Chemotherapeutic Drugs to Solid Tumors

Overview

Journal Pharm Res

Specialties Pharmacology
Pharmacy

Date 2010 Apr 29

PMID 20424894

Citations 59

Authors

Gerben A Koning

Alexander M M Eggermont

Lars H Lindner

Timo L M Ten Hagen

Affiliations

Soon will be listed here.

Abstract

Lipid-based nanocarriers or liposomes have been proven successful in the delivery of chemotherapeutic agents and are currently applied clinically in the treatment of various types of cancer. Liposomes offer the advantage of a high drug payload, decreased drug toxicity and enhanced drug accumulation at tumor sites. Increased accumulation is due to the relatively leaky tumor vasculature that allows liposome extravasation. Between different types of tumors and even within one tumor, vascular permeability and thus liposome extravasation may differ greatly. Furthermore, upon accumulation of liposomes in the tumor area, drug bioavailability is not guaranteed. At present, these are the major issues for clinically used liposomal drugs.Mild hyperthermia (HT), the heating of tumor tissue to temperatures of up to 43 degrees C, has been developed in the past decades as an established and efficacious treatment modality in combination with chemo- and radiotherapy. HT can be used to further improve liposomal chemotherapy in two ways: HT is known to increase vascular permeability in solid tumors and may therefore increase levels of liposome accumulation, and thermosensitive liposomes have been developed that can be triggered to release their contents upon hyperthermia. By applying these two strategies, drug delivery to tumors can be strongly enhanced.

Citing Articles

Heating Induced Nanoparticle Migration and Enhanced Delivery in Tumor Treatment Using Nanotechnology.

Gu Q, Zhu L Bioengineering (Basel). 2024; 11(9).

PMID: 39329642 PMC: 11428587. DOI: 10.3390/bioengineering11090900.

Regulation of CTLs/Tregs via Highly Stable and Ultrasound-Responsive Cerasomal Nano-Modulators for Enhanced Colorectal Cancer Immunotherapy.

Zhang J, Sun L, Jiang L, Xie X, Wang Y, Wu R Adv Sci (Weinh). 2024; 11(22):e2400485.

PMID: 38552151 PMC: 11165532. DOI: 10.1002/advs.202400485.

Investigating Doxorubicin's mechanism of action in cervical cancer: a convergence of transcriptomic and metabolomic perspectives.

Huang Z, Jing H, Lv J, Chen Y, Huang Y, Sun S Front Genet. 2023; 14:1234263.

PMID: 37701623 PMC: 10494242. DOI: 10.3389/fgene.2023.1234263.

Shining Gold Nanostars: From Cancer Diagnostics to Photothermal Treatment and Immunotherapy.

Vo-Dinh T, Liu Y, Crawford B, Wang H, Yuan H, Register J J Immunol Sci. 2023; 2(1):1-8.

PMID: 37600154 PMC: 10438859. DOI: 10.29245/2578-3009/2018/1.1104.

Enhancement of treatment efficacy of hepatic tumours using Trans-arterial-chemoembolization.

Pillai K, Ke K, Mekkawy A, Akhter J, Morris D Am J Cancer Res. 2023; 13(5):1623-1639.

PMID: 37293148 PMC: 10244111.

References

Dvorak H, Nagy J, Dvorak J, Dvorak A . Identification and characterization of the blood vessels of solid tumors that are leaky to circulating macromolecules. Am J Pathol. 1988; 133(1):95-109. PMC: 1880651. View

Franckena M, de Wit R, Ansink A, Notenboom A, Canters R, Fatehi D . Weekly systemic cisplatin plus locoregional hyperthermia: an effective treatment for patients with recurrent cervical carcinoma in a previously irradiated area. Int J Hyperthermia. 2007; 23(5):443-50. DOI: 10.1080/02656730701549359. View

Seynhaeve A, Hoving S, Schipper D, Vermeulen C, de Wiel-Ambagtsheer G, van Tiel S . Tumor necrosis factor alpha mediates homogeneous distribution of liposomes in murine melanoma that contributes to a better tumor response. Cancer Res. 2007; 67(19):9455-62. DOI: 10.1158/0008-5472.CAN-07-1599. View

Chen Q, Tong S, Dewhirst M, Yuan F . Targeting tumor microvessels using doxorubicin encapsulated in a novel thermosensitive liposome. Mol Cancer Ther. 2004; 3(10):1311-7. View

Yatvin M, Weinstein J, DENNIS W, Blumenthal R . Design of liposomes for enhanced local release of drugs by hyperthermia. Science. 1978; 202(4374):1290-3. DOI: 10.1126/science.364652. View

Alberts D, Muggia F, Carmichael J, Winer E, Jahanzeb M, Venook A . Efficacy and safety of liposomal anthracyclines in phase I/II clinical trials. Semin Oncol. 2005; 31(6 Suppl 13):53-90. DOI: 10.1053/j.seminoncol.2004.08.010. View

Ponce A, Viglianti B, Yu D, Yarmolenko P, Michelich C, Woo J . Magnetic resonance imaging of temperature-sensitive liposome release: drug dose painting and antitumor effects. J Natl Cancer Inst. 2007; 99(1):53-63. DOI: 10.1093/jnci/djk005. View

Ten Hagen T, van der Veen A, Nooijen P, van Tiel S, Seynhaeve A, Eggermont A . Low-dose tumor necrosis factor-alpha augments antitumor activity of stealth liposomal doxorubicin (DOXIL) in soft tissue sarcoma-bearing rats. Int J Cancer. 2000; 87(6):829-37. DOI: 10.1002/1097-0215(20000915)87:6<829::aid-ijc12>3.0.co;2-c. View

Lindner L, Eichhorn M, Eibl H, Teichert N, Schmitt-Sody M, Issels R . Novel temperature-sensitive liposomes with prolonged circulation time. Clin Cancer Res. 2004; 10(6):2168-78. DOI: 10.1158/1078-0432.ccr-03-0035. View

10.

Laginha K, Verwoert S, Charrois G, Allen T . Determination of doxorubicin levels in whole tumor and tumor nuclei in murine breast cancer tumors. Clin Cancer Res. 2005; 11(19 Pt 1):6944-9. DOI: 10.1158/1078-0432.CCR-05-0343. View

11.

Colombo R, Da Pozzo L, Salonia A, Rigatti P, Leib Z, Baniel J . Multicentric study comparing intravesical chemotherapy alone and with local microwave hyperthermia for prophylaxis of recurrence of superficial transitional cell carcinoma. J Clin Oncol. 2003; 21(23):4270-6. DOI: 10.1200/JCO.2003.01.089. View

12.

Kong G, Braun R, Dewhirst M . Characterization of the effect of hyperthermia on nanoparticle extravasation from tumor vasculature. Cancer Res. 2001; 61(7):3027-32. View

13.

Harrington K, Mohammadtaghi S, Uster P, Glass D, Peters A, Vile R . Effective targeting of solid tumors in patients with locally advanced cancers by radiolabeled pegylated liposomes. Clin Cancer Res. 2001; 7(2):243-54. View

14.

Koning G, Krijger G . Targeted multifunctional lipid-based nanocarriers for image-guided drug delivery. Anticancer Agents Med Chem. 2007; 7(4):425-40. DOI: 10.2174/187152007781058613. View

15.

Peller M, Schwerdt A, Hossann M, Reinl H, Wang T, Sourbron S . MR characterization of mild hyperthermia-induced gadodiamide release from thermosensitive liposomes in solid tumors. Invest Radiol. 2008; 43(12):877-92. DOI: 10.1097/RLI.0b013e31818768cd. View

16.

Kong G, Braun R, Dewhirst M . Hyperthermia enables tumor-specific nanoparticle delivery: effect of particle size. Cancer Res. 2000; 60(16):4440-5. View

17.

Li L, Ten Hagen T, Schipper D, Wijnberg T, van Rhoon G, Eggermont A . Triggered content release from optimized stealth thermosensitive liposomes using mild hyperthermia. J Control Release. 2010; 143(2):274-9. DOI: 10.1016/j.jconrel.2010.01.006. View

18.

Needham D, Anyarambhatla G, Kong G, Dewhirst M . A new temperature-sensitive liposome for use with mild hyperthermia: characterization and testing in a human tumor xenograft model. Cancer Res. 2000; 60(5):1197-201. View

19.

Unezaki S, Maruyama K, Takahashi N, Koyama M, Yuda T, Suginaka A . Enhanced delivery and antitumor activity of doxorubicin using long-circulating thermosensitive liposomes containing amphipathic polyethylene glycol in combination with local hyperthermia. Pharm Res. 1994; 11(8):1180-5. DOI: 10.1023/a:1018949218380. View